Creative Planning’s Cardiol Therapeutics CRDL Stock Holding History

Creative Planning’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.7K	Buy	+17,609	New	+$22.3K	﹤0.01%	4197

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Creative Planning's CRDL Position: Q2 2026 in Review

Creative Planning opened a new position in Cardiol Therapeutics (CRDL) in Q2 2026: 17,609 shares worth $18.7K. The stake represents ﹤0.01% of the portfolio and ranks #4197 among its holdings.

52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

Creative Planning held 17,609 shares of Cardiol Therapeutics worth $18.7K as of Q2 2026.
Cardiol Therapeutics was a new Creative Planning position in Q2 2026.
Cardiol Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #4197 holding.
52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.